Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
The Lancet. Oncology
|
October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.
The Oncologist
|
December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy
Lorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2021
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J Casak, Leigh Marcus, Lola Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
Sandra J Casak, Vaibhav Kumar, Chi Song, et al.
Current Epidemiology Reports
|
March 28, 2022
From Cancer Epidemiology to Policy and Practice: the Role of a Comprehensive Cancer Center
Robert A Hiatt, Amanda Sibley, Brinda Venkatesh, et al.
JCO Precision Oncology
|
August 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations
Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer
Sandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
The Lancet. Oncology
|
December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer
Suparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
The Lancet. Oncology
|
October 17, 2021
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Tatiana M Prowell, et al.
The Oncologist
|
December 21, 2020
Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy
Lorraine Pelosof, May Tun Saung, Martha Donoghue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2022
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 13, 2021
FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
Sandra J Casak, Leigh Marcus, Lola Fashoyin-Aje, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2024
FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
Sandra J Casak, Vaibhav Kumar, Chi Song, et al.
Current Epidemiology Reports
|
March 28, 2022
From Cancer Epidemiology to Policy and Practice: the Role of a Comprehensive Cancer Center
Robert A Hiatt, Amanda Sibley, Brinda Venkatesh, et al.
JCO Precision Oncology
|
August 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations
Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2023
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer
Sandra J Casak, M Naomi Horiba, Mengdie Yuan, et al.
The Lancet. Oncology
|
December 21, 2019
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J Gao, Joyce Cheng, Erik Bloomquist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer
Suparna Wedam, Preeti Narayan, Haley Gittleman, et al.
Page
of 8